April 1, 2022

Deciphex Appoints Dr. Trevor McKee to Spearhead Quantitative Pathology and Artificial Intelligence Service Delivery in Research Pathology

Deciphex is now a full service provider in Pathology AI and Quantitative Pathology, providing clients with best in class software, GPU infrastructure, AI and Data Science expertise, to maximize return on investment in AI and to deliver robust quantitative pathology outputs at a fraction of the cost and time of internal programs.  Deciphex is announcing that it has appointed Dr Trevor McKee as Director of Commercial AI Services for Research Pathology to spearhead this exciting initiative. 

Trevor received his PhD in Biological Engineering from the Massachusetts Institute of Technology and comes to Deciphex with 20 years of experience in Pathology Image Analysis and AI, including 10 years spent developing and managing computational pathology workflows for preclinical and clinical trial biomarkers in hospital core facilities and CROs. He has extensive experience building and managing technical teams while working collaboratively with pathologists, basic scientists, clinicians and pharmaceutical and CRO partners to build and deploy machine and deep learning-based algorithms for biomarker prediction in single and multiplex immunostaining assays, some of which are currently in use in clinical trials for monitoring of patient response. 

Trevor has 40+ publications in the areas of preclinical and translational research and computational pathology. He is also one of the founding members of the "Joint Effort to Develop multiplex Immunofluorescence Standards" or JEDIS council, where he works alongside clinicians and industry partners to jointly solve quality challenges and standardize assays in the field of Digital Pathology and Multiplex Immunostaining.

Trevor McKee - Director of Commercial AI Services

I’m very excited to join this excellent team, the ability to serve pathologists needs from early preclinical work through translational studies and into clinical practice, combined with state of the art AI capabilities and full service development really puts Deciphex in an excellent position to help our clients bring lifesaving treatments to market faster.

About Deciphex‍

Deciphex is an Irish-based software company focused on developing digital pathology-based solutions for clinical and research pathology. Our ambition is to deliver solutions that provide tangible productivity benefits to pathologists, eliminating low-level tasks so they can focus on the critical content. We believe that digital pathology combined with artificial intelligence will help make pathologists work more efficiently in the future, offering a solution to the pending challenges in supply/demand in pathology services. Deciphex is at the forefront of this revolution with cleverly positioned solutions that deliver on the biggest problems facing pathology today.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No items found.
return to news

Contact Details

Invent Buidling at DCU


DCU Alpha Building, Innovation Campus,
11 Old Finglas Rd, Glasnevin, Co. Dublin
D11 KXN4

Call: +353 1 582 7193

Email: Info@deciphex.com

Twitter: @deciphex

USA Headquarters Building


Deciphex Inc.
1012 95th Street, Naperville,
Chicago, Illinois

Call: +1 708 573 0674

Email: info@deciphex.com

USA Headquarters Building


Exeter Science Park Centre,
6 Babbage Way, Exeter

Call: +44 1 29730 2245

Email: Info@deciphex.com


Oxford Accessioning Centre (UK)
Diagnexia UK Limited,
John Eccles House
Robert Robinson Ave,

Email Us

The details you submit will be used so that we can contact you in relation to your query either by email or your preferred method of contact. Read our privacy policy here.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form
Copyright Deciphex 2021
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.